Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHKA | P35790 | 6/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | NCF1 | P14598 | 1/20 | 0.46 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22695032 | 0.95 | CHKA (0.44) | CHKASIGMAR1CA2NCF1PRMT6 | |
| SCHEMBL13915406 | 0.95 | CHKA (0.42) | CHKASIGMAR1CA2NCF1PRMT6 | |
| SCHEMBL27754853 | 0.92 | CYP2D6 (0.43) | CHKASIGMAR1CA2NCF1PRMT6 | |
| SCHEMBL20061255 | 0.91 | CHKA (0.43) | CHKASIGMAR1CA2NCF1PRMT6 | |
| SCHEMBL18121361 | 0.91 | CHKA (0.43) | CHKASIGMAR1CA2NCF1PRMT6 | |
| SCHEMBL13067395 | 0.89 | CYP2D6 (0.46) | CHKASIGMAR1CA2NCF1PRMT6 | |
| SCHEMBL81189 | 0.89 | — | — | |
| SCHEMBL6662807 | 0.89 | CHRNA7 (0.41) | SIGMAR1KDM4EALDH1A1 | |
| SCHEMBL17616057 | 0.89 | CHRNA7 (0.41) | SIGMAR1KDM4EALDH1A1 | |
| SCHEMBL14524205 | 0.89 | CHRNA7 (0.41) | SIGMAR1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 296 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-10203987-A | — | — | None | — | — | JP | disclosed |
| WO-2024141757-A1 | LSD1 MODULATORS | EXSCIENTIA AI LIMITED (GB) | 2024-07-04 | — | — | WO | disclosed |
| EP-4389223-A1 | SYNTHESIS, PHARMACOLOGY AND USE OF NEW WATER-SOLUBLE AND SELECTIVE FMS-LIKE TYROSINE KINASE 3 (FLT3) INHIBITORS | Universität Regensburg (DE) | 2024-06-26 | — | — | EP | disclosed |
| WO-2024020084-A1 | HETEROARYL COMPOUNDS AS LIGAND DIRECTED DEGRADERS OF IRAK4 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2024020380-A1 | QUINAZOLINE COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2023230542-A2 | PYRAZOLO[1,5-a]PYRIDINE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230338546-A1 | ORAL FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS | CARA THERAPEUTICS INC (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230338546-A1 | ORAL FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS | CARA THERAPEUTICS INC (US) | 2023-10-26 | — | — | US | disclosed |
| EP-1857459-A2 | Pyrazolopyrimidine compound and a process for preparing the same | TANABE SEIYAKU CO., LTD. (JP) | 2007-11-21 | — | — | EP | disclosed |
| US-20070155776-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABBVIE INC. | 2007-07-05 | — | — | US | disclosed |
| EP-1537111-B1 | HETEREOARYL NITRILE DERIVATIVES | NOVARTIS AG (CH) | 2007-05-02 | — | — | EP | disclosed |
| US-7211666-B2 | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-01 | — | — | US | disclosed |
| US-7202363-B2 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES (US) | 2007-04-10 | — | — | US | disclosed |
| US-20040097570-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | NEUROSEARCH A/S | 2004-05-20 | — | — | US | disclosed |
| US-20040097570-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | NEUROSEARCH A/S | 2004-05-20 | — | — | US | disclosed |
| WO-2004020441-A1 | HETEREOARYL NITRILE DERIVATIVES | NOVARTIS AG (CH) | 2004-03-11 | — | — | WO | disclosed |
| WO-2000078728-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS COMPRISING THESE COMPOUNDS | NEUROSEARCH A/S (DK) | 2000-12-28 | — | — | WO | disclosed |
| JP-H10203987-A | AGENT CONTAINING (R)-1-ETHYL-4-METHYLHEXAHYDRO-1H-1,4-DIAZEPINE DERIVATIVE AS ACTIVE COMPONENT AND EFFECTIVE FOR SUPPRESSING VOMITION INDUCED BY MORPHINE-LIKE AGENT | DAINIPPON PHARMACEUT CO LTD | 1998-08-04 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097570-A1 | Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds | GABRA1, GABRA2, GABRA4 | CHKA 1267/4885SIGMAR1 831/4885CA2 407/4885 |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | IKZF1, IKZF3, IKZF2 | CHKA 779/4885SIGMAR1 4230/4885CA2 4527/4885 |
| US-20230338546-A1 | ORAL FORMULATIONS OF KAPPA OPIOID RECEPTOR AGONISTS | OPRK1, OPRL1, OGFR | CHKA 790/4885SIGMAR1 66/4885CA2 1565/4885 |
| US-20070155776-A1 | THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS | ABL1, ERBB2, LCK | CHKA 392/4885SIGMAR1 4564/4885CA2 1789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.